We’ve also had conversations with our pharma partners, and interestingly many of those who we’ve talked to with the intent of focusing on myeloma are actually taking a bigger picture view and looking across their portfolios to think about how they might proactively leverage MRD, MRD more prospectively in anticipation of the FDA potentially being more open to MRD data across hematologic malignancies in the fourth coming time.
Unidentified Analyst: Great. Thank you very much.
Operator: Thank you very much. One moment for our next question. Our next question comes from Andrew Brackmann of William Blair. Andrew, your line is open.
Unidentified Analyst: Hi, everyone. This is Maggie Builian [ph] for Andrew today. I wanted to ask one on the progress of the EMR integration. I know you spoke to earlier some strong growth in the quarter from customers, but just wanted to know what feedback has been for the accounts that you’ve recently added, and then how many more accounts do you expect to be able to add this year, and then how is this factoring into gross assumptions?
Susan Bobulsky: Yes. Thank you for our questions, Maggie. We are hearing very positive feedback. As you might imagine, it makes the assay significantly easier to use both from an ordering perspective and in terms of integrating the results directly into the patients chart for clinical use. We have nine active projects that Chad mentioned currently in motion with IT departments at the specific sites. We have dozens of additional sites that are in conversation securing IT resources going through various approval processes. We are ready to go with any account that’s ready to move. I’ll note that some of the accounts that are in active IT development are among our largest accounts. In fact, 15 of our 20 largest accounts are Epic customers, so we’re very eager to move those forward and to ensure that a meaningful portion of our volume goes through Epic over the next one to two years.
We do anticipate by the end of this year, continue to expect between 20 and 25 accounts to be integrated. That’ll represent somewhere between 15 and 20 percent of our volume we expect. We expect to continue to increase the speed whereby we can get these accounts up and running. Our most recent projects are trending toward about a seven-week timeline, which is really nicely aligned with industry standards for our integration.
Unidentified Analyst: Great, thank you so much. And I wanted to ask another one on improving gross margins. One of the drivers to reach your profitability target frame are RD. Can you talk about the progress of some of the initiatives there, such as the transition to NovaSeq and the LIMS overhaul and how these are progressing? How should we be thinking about these driving improvements in gross margins over time? Thank you.
Chad Robins: Yes, I think first and foremost on the gross margins ASP initiatives, we’re starting to see some of that pull through with some strong collections subsequent to the quarter. As it relates to the costing profile of the assay with the transition to NovaSeq, I think of that as a 25 event. We’re still undergoing the development aspects of that and assessing that. I view that as 25. Then I think the other thing to just note is overall as a company, we’re going to continue to look at everything we can do to line operations and continue to gain leverage without increasing expenses to get to that profitability metric. So I think of leveraging our field force as just as important as what we do in the margin profile business.
Unidentified Analyst: Great, thank you so much.
Operator: Thank you very much. At this time, I’m showing no further questions in the queue. This will conclude our question-and-answer session. Thank you for participating in today’s conference. This does conclude the program. You may now disconnect.
Chad Robins: Thank you.
